{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T06:27:12Z","timestamp":1774592832586,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2001,10,1]],"date-time":"2001-10-01T00:00:00Z","timestamp":1001894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2001,10,1]],"date-time":"2001-10-01T00:00:00Z","timestamp":1001894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2001,10,1]]},"DOI":"10.1038\/sj.bmt.1703200","type":"journal-article","created":{"date-parts":[[2002,9,17]],"date-time":"2002-09-17T16:38:49Z","timestamp":1032280729000},"page":"637-642","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":139,"title":["An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis"],"prefix":"10.1038","volume":"28","author":[{"given":"V","family":"Sanchorawala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DG","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DC","family":"Seldin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LM","family":"Dember","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Finn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RH","family":"Falk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Berk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Quillen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Skinner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2001,11,1]]},"reference":[{"key":"BF1703200_CR1","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1056\/NEJM199709253371306","volume":"337","author":"RH Falk","year":"1997","unstructured":"Falk RH, Comenzo RL, Skinner M . The systemic amyloidoses New Engl J Med 1997 337: 898\u2013909","journal-title":"New Engl J Med"},{"key":"BF1703200_CR2","first-page":"45","volume":"32","author":"RA Kyle","year":"1995","unstructured":"Kyle RA, Gertz MA . Primary systemic amyloidosis: clinical and laboratory features in 474 cases Semin Hematol 1995 32: 45\u201359","journal-title":"Semin Hematol"},{"key":"BF1703200_CR3","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood.V93.3.1062","volume":"93","author":"RA Kyle","year":"1999","unstructured":"Kyle RA, Gertz MA, Greipp PR et al. Long-term survival (10 years or more) in 30 patients with primary amyloidosis Blood 1999 93: 1062\u20131066","journal-title":"Blood"},{"key":"BF1703200_CR4","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/S0002-9343(97)89487-9","volume":"100","author":"M Skinner","year":"1996","unstructured":"Skinner M, Anderson J, Simms R et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone and colchicine versus colchicine only Am J Med 1996 100: 290\u2013298","journal-title":"Am J Med"},{"key":"BF1703200_CR5","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1056\/NEJM199704243361702","volume":"336","author":"RA Kyle","year":"1997","unstructured":"Kyle RA, Gertz MA, Greipp PR et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone and colchicine New Engl J Med 1997 336: 1202\u20131207","journal-title":"New Engl J Med"},{"key":"BF1703200_CR6","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1200\/JCO.1999.17.1.262","volume":"17","author":"MA Gertz","year":"1999","unstructured":"Gertz MA, Lacy MQ, Lust JA et al. Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis J Clin Oncol 1999 17: 262\u2013267","journal-title":"J Clin Oncol"},{"key":"BF1703200_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma New Engl J Med 1996 335: 91\u201395","journal-title":"New Engl J Med"},{"key":"BF1703200_CR8","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1182\/blood.V88.7.2801.bloodjournal8872801","volume":"88","author":"RL Comenzo","year":"1996","unstructured":"Comenzo RL, Vosburgh E, Simms RW et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients Blood 1996 88: 2801\u20132806","journal-title":"Blood"},{"key":"BF1703200_CR9","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1182\/blood.V91.10.3662","volume":"91","author":"RL Comenzo","year":"1998","unstructured":"Comenzo RL, Vosburgh E, Falk RH et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients Blood 1998 91: 3662\u20133670","journal-title":"Blood"},{"key":"BF1703200_CR10","first-page":"396a","volume":"94","author":"V Sanchorawala","year":"1999","unstructured":"Sanchorawala V, Wright DG, Dember LM et al. Five years experience with high dose intravenous melphalan and autologous peripheral blood stem cell transplantation for the treatment of patients with AL amyloidosis Blood 1999 94: 396a","journal-title":"Blood"},{"key":"BF1703200_CR11","doi-asserted-by":"publisher","first-page":"746","DOI":"10.7326\/0003-4819-134-9_Part_1-200105010-00011","volume":"134","author":"LM Dember","year":"2001","unstructured":"Dember LM, Sanchorawala V, Seldin DC et al. Effect of dose-intensive intravenous melphalan and autologous blood stem cell transplant on AL amyloidosis-associated renal disease Ann Intern Med 2001 134: 746\u2013753","journal-title":"Ann Intern Med"},{"key":"BF1703200_CR12","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1182\/blood.V97.6.1885","volume":"96","author":"E Choufani","year":"2001","unstructured":"Choufani E, Sanchorawala V, Skinner M et al. Acquired factor X deficiency in patients with AL amyloidosis: incidence, bleeding manifestations, and response to high dose therapy Blood 2001 96: 1885\u20131887","journal-title":"Blood"},{"key":"BF1703200_CR13","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/sj.bmt.1702643","volume":"26","author":"MA Gertz","year":"2000","unstructured":"Gertz MA, Lacy MQ, Gastineau DA et al. Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL) Bone Marrow Transplant 2000 26: 963\u2013969","journal-title":"Bone Marrow Transplant"},{"key":"BF1703200_CR14","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/sj.bmt.1702178","volume":"25","author":"MA Gertz","year":"2000","unstructured":"Gertz MA, Lacy MQ, Dispenzieri A . Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report Bone Marrow Transplant 2000 25: 465\u2013470","journal-title":"Bone Marrow Transplant"},{"key":"BF1703200_CR15","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1046\/j.1365-2141.1998.00772.x","volume":"101","author":"P Moreau","year":"1998","unstructured":"Moreau P, Leblond V, Bourquelot P et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients Br J Haematol 1998 101: 766\u2013769","journal-title":"Br J Haematol"},{"key":"BF1703200_CR16","unstructured":"Gillmore JD, Apperley JF, Craddock C et al. High-dose melphalan and stem cell rescue for AL amyloidosis. VIII International Symposium on Amyloidosis. Mayo Clinic: Rochester, MN. August 7\u201311, 1998 p 102"},{"key":"BF1703200_CR17","first-page":"660a","volume":"10","author":"N Saba","year":"1998","unstructured":"Saba N, Tsang R, Sutton DM et al. High treatment-related mortality in cardaic amyloid patients supports the use of less intensive, non-cardiotoxic PBSC collection and induction regimens Blood 1998 10: (Suppl. 1) 660a","journal-title":"Blood"},{"key":"BF1703200_CR18","first-page":"20a","volume":"18","author":"A Dispenzieri","year":"1999","unstructured":"Dispenzieri A, Lacy MQ, Kyle RA et al. AL amyloidosis is a favorable independent prognostic factor for survival of 234 patients with primary systemic amyloidosis (AL) functionally eligible for peripheral blood stem cell transplantation Proc ASCO 1999 18: 20a","journal-title":"Proc ASCO"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1703200","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1703200.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1703200.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T22:30:53Z","timestamp":1648074653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1703200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,10,1]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2001,10,1]]}},"alternative-id":["BF1703200"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1703200","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,10,1]]},"assertion":[{"value":"1 November 2001","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}